Import Alert 89-08: Reconciling Lost US Revenue Under Ind AS 115

An illustrative Tier-1 Indian pharma formulator with a large US-market injectable footprint receives a USFDA Import Alert 89-08 listing on its Hyderabad-area injectable plant with effect from April 2026. Shipments dispatched from the plant across February and March 2026 (of the order of USD 42 million FOB, illustrative) that have already sailed and are at or approaching the US port are placed on Detention Without Physical Examination on release inspection. Import Alert 89-08 is issued under Section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act — the CGMP-non-conformity limb of the US adulteration definition — and applies to specific manufacturing categories at the listed plant rather than to the plant’s entire product portfolio. From the moment of listing, the finance team faces a compound accounting problem: the revenue on the shipped-but-detained batches no longer meets the Ind AS 115 paragraph-56-to-58 highly-probable-of-non-reversal threshold and must be reversed; the corresponding inventory is restored to the balance sheet under Ind AS 2 at the lower of cost and net realisable value, with the net realisable value materially compromised because the primary US channel is closed until the plant is removed from the alert; an Ind AS 37 provision must be recognised for US-port demurrage, restocking, destruction and buyer-indemnity outflow; the Section 54(3) LUT-bond export-side IGST refund cycle continues unaffected because the Indian export STATUS is intact; and any refund flow to the US buyer must be gated through Section 195 TDS with a DTAA and Tax Residency Certificate overlay. This article walks through the Import Alert 89-08 lost US revenue Ind AS 115 pharma reconciliation surface at the shipment-level granularity that the alert scoping demands.

Quick reference

The reconciliation in one paragraph

An Import Alert 89-08 listing at an Indian pharma formulator’s US-market injectable plant sets off a five-surface reconciliation cascade at the next reporting date. Surface one is the Ind AS 115 revenue reassessment — the paragraph-57 external-regulatory-factor test breaks the highly-probable threshold at paragraph 56 for the shipped-but-detained batches on alert-affected SKUs, and the revenue is reversed in the current period as a change in accounting estimate under Ind AS 8. Surface two is the Ind AS 2 inventory restoration — the reversed cost of goods sold restores the batches to inventory at the US port, measured at the lower of cost and net realisable value, with net realisable value materially compromised because the primary US channel is closed. Surface three is the Ind AS 37 provision for US-port demurrage, restocking, destruction, and any buyer-indemnity outflow under the supply-agreement’s regulatory-action clause. Surface four is the Section 54(3) export-side IGST refund continuity — the Indian export STATUS is anchored to the pre-alert shipping bill and export general manifest, so the monthly Form GST RFD-01 refund cycle on the accumulated export-side ITC is unaffected by the destination-country alert. Surface five is the Section 195 TDS treatment on any refund payment to the US buyer, with the refund split between return-of-consideration (no TDS) and consequential-loss compensation (DTAA-modulated TDS with a Tax Residency Certificate on file under Section 90(4)). Each surface is a distinct reconciliation and each rolls forward monthly until the plant is removed from the alert and prospective revenue recognition can resume.

What the scenario looks like in India

The Indian pharma industry runs a significant share of the world’s generic injectable, ophthalmic, and sterile-dosage shipments to the US market. USFDA inspection remains the single largest external regulatory event on the finance calendar, and Import Alert listings — Import Alert 66-40 for plant-wide Detention Without Physical Examination, Import Alert 89-08 for specific manufacturing category CGMP-non-conformity, Import Alert 99-32 for detention-with-cause — periodically feature across the Tier-1 and Tier-2 formulator plants that supply the US market. Historical inspection cycles have touched plants across Sun Pharmaceutical Industries (Halol, Dadra, Karkhadi), Aurobindo Pharma (multiple US-market injectable units including Hyderabad-area sites), Dr Reddy’s Laboratories (Bachupally, Bollaram, the Cuernavaca Mexico plant), Glenmark Pharmaceuticals (Halol, Baddi, Monroe NJ), Lupin (Somerset NJ, Coral Springs), Zydus Lifesciences (Moraiya, Ahmedabad), Cipla (Goa, Kurkumbh), Torrent Pharmaceuticals (Indrad), Piramal Pharma Solutions (Digwal), and Divi’s Laboratories (Vishakhapatnam, Kakinada). Injectable manufacturing surfaces are typically subject to the most demanding CGMP scrutiny under 21 CFR Part 211 subpart F on production and process controls and subpart G on packaging and labelling, and are consequently the surface where Import Alert 89-08 listings most frequently attach.

For the illustrative worked example in this article, the reference persona is an Aurobindo-scale Tier-1 integrated formulator’s US-market-facing injectable plant unit in the Hyderabad manufacturing belt — the kind of unit that operates 24x7 sterile-fill and lyophilisation lines, ships to a rolling roster of large US generic distributors, and carries a standing US-market injectable revenue footprint of the order of USD 350 to 500 million annually across all shipping SKUs. The persona is illustrative — real Import Alert 89-08 listings, their SKU scoping, and per-plant per-month revenue impact are disclosed by the USFDA on the public Import Alert database and by the affected listed company through stock-exchange disclosure, and are not the subject of speculative recomputation here. The point of the persona is the reconciliation surface, not the identity of any specific real event.

The regulatory overlay — FDCA 501(a)(2)(B), Ind AS 115 paragraphs 56 to 58, Ind AS 37, Section 54(3), Section 195

Five regulatory anchors govern the reconciliation surface and each maps to a distinct workbook component.

Section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (codified at 21 USC 351) deems a drug to be adulterated if the methods used in, or the facilities or controls used for, its manufacture, processing, packing or holding do not conform to or are not operated or administered in conformity with current good manufacturing practice. An Import Alert issued under this provision authorises US Customs and Border Protection and USFDA field officers to detain the listed products at the US port without physical examination — the mechanic known as Detention Without Physical Examination or DWPE — pending removal of the plant from the alert list through corrective action satisfactory to the agency. Import Alert 89-08 is the specific alert instrument covering manufacturing categories where the USFDA has made a 501(a)(2)(B) determination; the alert scoping typically identifies the affected plant, the affected manufacturing category (an injectable line, a specific dosage-form category, a specific product family), and the effective date of listing. Prospective and retrospective shipments of alert-affected SKUs are subject to detention at the US port from the effective date forward.

Ind AS 115 (Revenue from Contracts with Customers), notified by the Ministry of Corporate Affairs under the Companies (Indian Accounting Standards) Rules 2015, governs revenue recognition. Paragraphs 56 to 58 constrain the recognition of variable consideration. Paragraph 56 requires that variable consideration is included in the transaction price only to the extent that it is highly probable that a significant reversal in cumulative revenue will not occur when the uncertainty is resolved. Paragraph 57 lists factors that reduce the likelihood of meeting the highly-probable threshold — including that the amount of consideration is highly susceptible to factors outside the entity’s influence, and that the entity’s experience with similar types of contracts is limited. An Import Alert listing on the manufacturing plant is a textbook paragraph-57 external-regulatory-factor — the shipment consideration is now highly susceptible to the USFDA’s decision on release, which is outside the entity’s control until the alert is lifted. Paragraph 58 requires reassessment at each reporting date. The reassessment for the alert-affected shipped-but-detained batches typically concludes that the highly-probable threshold is not met, and the revenue is reversed as a change in accounting estimate under Ind AS 8 (not as an error correction). The USFDA warning letter Ind AS 37 provision guide walks the sibling case where the remediation cost provision is recognised at the warning-letter stage; the Import Alert 89-08 case adds the paragraph-56-to-58 revenue-reversal layer on top of the provision workflow.

Ind AS 37 (Provisions, Contingent Liabilities and Contingent Assets) applies to the post-listing outflows that the formulator faces on the detained shipments. Paragraph 14’s three-limb recognition test is met at listing — the past event is the Import Alert 89-08 issuance; the probable outflow is the US-port demurrage and storage cost that begins to accrue on detention, the buyer restocking or return-freight cost, the potential product destruction cost where re-export to a third country is not economic, and any buyer indemnity payable under the supply-agreement’s regulatory-action clause; the reliable estimate is built through the shipment-level FOB register and the initial buyer-consultation scoping. Paragraph 36 requires measurement at the best-estimate figure. The USFDA Form 483 remediation cost accounting treatment guide covers the parallel provision workflow that runs on the same plant for the underlying remediation cost that will ultimately support the alert removal.

Section 54(3) of the CGST Act 2017, read with Section 16 of the IGST Act 2017 and Rule 96A of the CGST Rules 2017, governs the export-side IGST refund cycle on accumulated unutilised ITC. The Indian export STATUS of a shipment — which is the anchor for Section 54(3) refund eligibility — is established at the point of filing the shipping bill and export general manifest with Indian Customs, and confirmed on export general manifest date when the vessel or aircraft departs India. The shipments dispatched pre-alert have completed their Indian export cycle before the alert took effect; the Indian LUT-bond mechanism is unaffected. The formulator’s monthly Form GST RFD-01 refund cycle on the export-side accumulated ITC — which for an injectable plant typically comprises Chapter 27 solvents at 18 percent, Chapter 30 API purchases at 5 percent, Chapter 39 and 48 packaging at 18 percent, and Chapter 40 rubber closures and vial-stopper components at 18 percent — continues to run against the pre-alert shipping bill export turnover. This is a critical continuity — the export-side refund cycle for the Aurobindo-scale plant persona in this article typically runs in the Rs 25 to 45 crore per month range and its continuity through the alert period is a material treasury item. The mechanic connects to the broader Rule 89(5) inverted-duty refund pharma formulations complete guide for the domestic Chapter 30 output-inversion refund, but on the export leg the LUT-bond zero-rated-supply refund is a distinct mechanic and is governed by the Section 16 IGST Act 2017 framework rather than the Section 54(3) inverted-duty leg alone.

Section 195 of the Income-tax Act 2025 (successor to Section 195 of the Income-tax Act 1961) governs TDS on payments to non-residents. Any refund flow from the Indian formulator to the US buyer for the shipped-but-detained consignment must be split between the return-of-consideration component (not chargeable to tax; no TDS) and the consequential-loss compensation component (potentially chargeable to tax; DTAA-modulated TDS with a Tax Residency Certificate on file under Section 90(4)). The India-USA Double Taxation Avoidance Agreement — typically Article 22 for other income or Article 7 for business profits — modulates the TDS rate on the DTAA-attributable share. The reconciliation discipline holds the two components in a distinct working with the DTAA article reference, the TRC on-file flag, and the Form 27EQ quarterly TDS return line for each refund payment.

A worked example — an illustrative Aurobindo-scale injectable plant on Import Alert 89-08 from April 2026

Illustrative — the following figures represent the reconciliation surface for an illustrative Tier-1 integrated formulator’s US-market-facing injectable plant unit on an Import Alert 89-08 listing. Public disclosures do not reveal shipment-level FOB volumes or per-batch alert-scoping impact at the granularity below; cross-verify against your own plant’s shipping-bill register, US-buyer correspondence, and USFDA Import Alert database entry before action.

The persona is an Aurobindo-scale integrated formulator’s injectable plant unit in the Hyderabad manufacturing belt. Historical US-market injectable revenue from the unit runs at USD 350 million annualised across a rolling roster of sterile-fill and lyophilised-injectable SKUs. In February and March 2026, the unit dispatches shipments totalling USD 42 million FOB across 14 shipping bills to a mix of large US generic distributors under standing supply agreements. The shipments physically leave India on export general manifest dates spread across the two months; the corresponding GSTR-1 zero-rated outward supply entries are filed on time; the LUT registration in Form GST RFD-11 for FY 2025-26 is valid and on file; the export-side IGST refund cycle continues to file monthly against the accumulated ITC.

On 15 April 2026 the USFDA publishes an Import Alert 89-08 listing that includes the Hyderabad-area unit for the sterile-injectable manufacturing category. Effective 15 April 2026, all injectable shipments from the unit are subject to Detention Without Physical Examination at the US port. The 14 pre-alert shipments (USD 42 million FOB) are at various stages of sea and air transit; on arrival at the US port they are placed on DWPE. US-buyer notifications reach the plant’s export-desk within 48 hours of the first arrival. The finance team’s Q4 FY 2025-26 reporting date (31 March 2026) has passed and the alert is a post-balance-sheet-date event; the Q1 FY 2026-27 reporting date (30 June 2026) is the first reporting date at which the reassessment is booked.

The 30 June 2026 reporting-date reconciliation shows:

The net profit and loss impact for Q1 FY 2026-27 on the Import Alert 89-08 event is: revenue reversal Rs (348.6) crore, plus cost of goods sold reversal Rs 243.0 crore, less Ind AS 2 inventory writedown Rs 218.7 crore (booked as further COGS charge), less Ind AS 37 provision Rs 77.9 crore, equal to a net negative impact of the order of Rs 402.2 crore on the quarter’s profit — before any income-tax adjustment. The Ind AS 8 accounting-estimate-change disclosure in Note X to the Q1 FY 2026-27 accounts explains the reassessment; the Ind AS 37 movement schedule under paragraph 84 shows the four provision limbs as separate lines. The Section 54(3) export-side IGST refund cycle continues unaffected — the June 2026 Form GST RFD-01 filing shows Rs 32 crore against the export turnover reported on the shipping-bill dates that pre-date the alert.

From July 2026 forward, prospective US-market shipments from the affected unit are suspended pending remediation. The remediation programme — CGMP corrective action, external CGMP-consultant engagement, follow-up USFDA re-inspection — typically runs 12 to 24 months to a closure re-inspection outcome. During the remediation cycle, each subsequent reporting date carries a fresh Ind AS 37 provision reassessment for demurrage-and-storage accrual on any still-detained inventory, updated net realisable value estimates as the buyer-negotiation and third-country re-export options mature or close, and updated Section 195 TDS reconciliation for actual refund payments made in the period. Once the plant is removed from Import Alert 89-08, prospective US-market revenue recognition resumes on a fresh Ind AS 115 assessment — the highly-probable threshold is re-established as the paragraph-57 external-regulatory-factor is removed.

Common reconciliation breakages

Four breakages recur across Indian pharma formulator finance teams handling Import Alert 89-08 events, and each maps to a specific control failure.

• Revenue reversal booked at the wrong reporting date. The alert-listing date and the Detention Without Physical Examination confirmation are the trigger events for the paragraph-58 reassessment, but the reversal is booked in the reporting period in which the reassessment concludes — not retrospectively into the reporting period in which the original revenue was recognised. Formulators that book the reversal as a prior-period restatement (error correction under Ind AS 8) rather than a current-period change in accounting estimate distort both the comparative-period accounts and the current-period tax computation. The correct treatment is a current-period change in estimate with prospective effect and disclosure in Note X. The reconciliation failure-mode analysis for India methodology treats the reassessment-timing decision as a specific control test with a documented sign-off point.

• Ind AS 2 net realisable value not distinguished from Ind AS 37 provision. The two accounting entries look similar in cash-impact terms but are conceptually distinct. The Ind AS 2 net realisable value writedown reduces the carrying value of the shipped-but-detained inventory below cost where the third-country re-export or destruction outcome makes cost non-recoverable. The Ind AS 37 provision covers the outflow-related cost buckets — demurrage, restocking, destruction, buyer indemnity — that are additional to the inventory value itself. Formulators that fold both into a single “impairment” line lose the audit-trail granularity that the Ind AS 8 disclosure requires and lose the ability to separately track the movement of each bucket in subsequent reporting periods. The reconciliation discipline is to hold the two workings distinct, with a bridge line showing the aggregate P&L impact.

• Section 54(3) LUT-bond export-side IGST refund cycle wrongly suspended. The most common defensive-reflex error is to suspend the monthly Form GST RFD-01 filing under the mistaken assumption that the destination-country Import Alert retrospectively affects the Indian export status. The Indian export STATUS is anchored to the shipping bill and export general manifest — pre-alert filings are unaffected. Suspending the refund cycle creates an unnecessary Rs 25 to 45 crore per month working-capital hit for a plant of the illustrative persona’s scale and, worse, may cause the refund claim to slip past the two-year filing window under Section 54 if the suspension continues for an extended remediation cycle. Reconciliation discipline: the export-side refund cycle continues unaffected; the domestic-side Rule 89(5) inverted-duty refund cycle for any non-US-market output from the same plant also continues; and the reconciliation workbook holds a distinct continuity confirmation line for each cycle.

• Section 195 TDS split between return-of-consideration and consequential-loss not documented. Formulators that treat the entire US-buyer refund as a single payment with a single TDS treatment either over-deduct (applying TDS to the return-of-consideration component that carries no TDS liability) or under-deduct (missing the consequential-loss component that is potentially chargeable under Section 195). The reconciliation discipline is to split the payment at the accounting entry, apply the appropriate TDS treatment to each component, hold the supporting supply-agreement clause and buyer TRC on file, and reconcile to the Form 27EQ quarterly TDS return line. The 57 errors and detection envelope framework is a useful cross-reference for the class of errors that arise from mis-classification of composite payments.

How a reconciliation platform handles this

A purpose-built pharma reconciliation platform ingests the plant-level shipping-bill export register, the SAP FI or Oracle Fusion revenue and COGS ledger, the USFDA Import Alert database extract with per-plant per-SKU alert scoping and effective dates, the US-buyer correspondence and detention notification feed, and the LUT registration and monthly Form GST RFD-01 filing register — and produces a monthly reporting-date Import Alert 89-08 reconciliation pack that isolates the alert-affected shipments at batch-level granularity, computes the Ind AS 115 paragraph-56-to-58 revenue reversal with the accompanying cost of goods sold restoration, holds the Ind AS 2 net realisable value writedown separately from the Ind AS 37 provision for demurrage-restocking-destruction-indemnity, confirms the Section 54(3) LUT-bond export-side IGST refund cycle continuity, and gates any refund payment to the US buyer through the Section 195 TDS split between return-of-consideration and consequential-loss with the DTAA article and TRC treatment applied per payment. Match rate improvement of 51 to 88 percent on the shipment-level shipping-bill-to-revenue-ledger reconciliation, combined with an ISO 27001:2022 posture and DPDP Act 2023 aligned data handling, is what makes the platform an infrastructure investment for a Tier-1 pharma formulator running a multi-plant US-market injectable footprint rather than a spreadsheet substitute.

Cross-cluster bridges and where to read next

The Import Alert 89-08 recognition-and-measurement cycle in this article sits alongside the USFDA remediation-cost provisioning workflow that runs on the same plant. The USFDA warning letter Ind AS 37 provisions and contingent liabilities walkthrough covers the sibling recognition test at the warning-letter stage that typically precedes an Import Alert 89-08 listing; the USFDA Form 483 remediation cost accounting treatment guide is the earlier-stage anchor at the Form 483 observation stage. The export-side IGST refund cycle that continues unaffected through the alert period sits alongside the domestic Chapter 30 output-inversion refund cycle covered in the Rule 89(5) inverted-duty refund for pharma formulations complete guide.

The methodology framework for building the shipment-level reconciliation workbook, holding each accounting standard as a distinct workbook component, and running a monthly reassessment feed against the remediation-and-closure cycle sits in Terra Insight’s own reconciliation failure-mode analysis pillar and the reconciliation playbook monthly close operations pillar. The commercial pillar for the pharma sub-cluster is Pharma reconciliation software India; the broader authority for the platform is reconciliation software India with the specialised GST reconciliation software surface for the Section 54(3) LUT-bond export refund workflow.

The five FAQs below address the operational questions Indian pharma finance controllers and export-desk leads ask most often when a plant transitions from a Form 483 observation cycle through a warning letter to an Import Alert 89-08 listing.

Terra Insight Editorial Team Reconciliation Infrastructure

Content authored by practitioners with experience at Amazon India, Intuit QuickBooks, and the Tata Group. Meet the team →

Published 16 July 2026

Domain expertise

TDS Reconciliation GST Input Credit Platform Settlements NACH Batch Matching Bank Reconciliation Form 26AS Matching ERP Integrations Enterprise Finance Ops

Reviewed by

NK

Navin Krishnan

Managing Director & Founder — Terra Insight

Ex Amazon India · Intuit QuickBooks · Tata nexarc

ISO 27001:2022 Patent Pending Incorporated 2024